NervGen Pharma Corp (NGEN) - Total Assets
Based on the latest financial reports, NervGen Pharma Corp (NGEN) holds total assets worth CA$13.08 Million CAD (≈ $9.46 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore NervGen Pharma Corp (NGEN) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
NervGen Pharma Corp - Total Assets Trend (2017–2024)
This chart illustrates how NervGen Pharma Corp's total assets have evolved over time, based on quarterly financial data. See NGEN book value for net asset value and shareholders' equity analysis.
NervGen Pharma Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
NervGen Pharma Corp's total assets of CA$13.08 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 88.6% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$464.96K | 2.4% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how NervGen Pharma Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NGEN market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NervGen Pharma Corp's current assets represent 97.6% of total assets in 2024, an increase from 0.0% in 2017.
- Cash Position: Cash and equivalents constituted 88.6% of total assets in 2024, up from 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 2.4% of total assets.
NervGen Pharma Corp Competitors by Total Assets
Key competitors of NervGen Pharma Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
NervGen Pharma Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 1.66 | 8.21 |
| Quick Ratio | 0.79 | 1.66 | 8.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.36 Million | CA$8.70 Million | CA$5.45 Million |
NervGen Pharma Corp - Advanced Valuation Insights
This section examines the relationship between NervGen Pharma Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 189.48 |
| Latest Market Cap to Assets Ratio | 15.14 |
| Asset Growth Rate (YoY) | 47.2% |
| Total Assets | CA$19.49 Million |
| Market Capitalization | $295.10 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NervGen Pharma Corp's assets at a significant premium (15.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: NervGen Pharma Corp's assets grew by 47.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NervGen Pharma Corp (2017–2024)
The table below shows the annual total assets of NervGen Pharma Corp from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$19.49 Million ≈ $14.10 Million |
+47.22% |
| 2023-12-31 | CA$13.24 Million ≈ $9.57 Million |
-44.56% |
| 2022-12-31 | CA$23.88 Million ≈ $17.27 Million |
+33.41% |
| 2021-12-31 | CA$17.90 Million ≈ $12.95 Million |
+168.10% |
| 2020-12-31 | CA$6.68 Million ≈ $4.83 Million |
-1.33% |
| 2019-12-31 | CA$6.77 Million ≈ $4.89 Million |
+118.43% |
| 2018-12-31 | CA$3.10 Million ≈ $2.24 Million |
+3620.63% |
| 2017-12-31 | CA$83.25K ≈ $60.22K |
-- |
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more